Main Article Content

Kinjalka Ghosh
M G Muddeshwar
Monoj Lokhande
Kanjaksha Ghosh


Malaria, Complicated malaria, Cobalt albumin binding assay, Vivax malaria, Falciparum malaria.


Background :  We evaluated albumin cobalt binding (ACB) assay as a prognostic marker for severe malaria  in a medical college setting .

Methods :Consecutive adult patients admitted with both vivax and falciparum malaria were evaluated with ACB assay at the time of admission. Detailed work up and individual patient directed management were instituted in addition to immediate artemisin based antimalarial therapy.

Results :100 consecutive patient ( 50 with vivax and 50 with falciparum malaria ) were evaluated . Reference range for ACB assay was established using 50 adult healthy ( 25 male and 25 female ) individuals . 16 out of 50 p. falciparum infected developed complicated malaria. All malaria infected patients had high ACB levels ( P<0.0001). There was step wise increase in ACB levels from healthy volunteers to different category of malaria( P<0.0001 ) without any overlap.


Conclusion: ACB can be used as a robust simple and cheap prognostic marker for organ dysfunction in  severe malaria.


Download data is not yet available.
Abstract 1988 | PDF Downloads 421 HTML Downloads 937


[ 1]. Dash AP , Valecha N, Anvikar AR,and Kumar A. Malaria in India: Challenges and opportunities J. Biosci. 2008, 33 :583–592.
[ 2]. Chen Q, Schlichtherle M,and Wahlgren M. Molecular aspects of severe malaria.Clinical Microbiology reviews , 2000, 13:439–450.
[3]. Dondorp AM . Pathophysiology, clinical presentation and treatment of cerebral malaria. Neurology Asia 2005; 10 : 67 – 77.
[4]. Marta M.M.F. Duarte, João B.T. Rocha, Rafael N. M, Thiago D, Da CruzI BM , LoroVL , Schetinger MRC . Association between ischemia- modified albumin, lipids and inflammation biomarkers in patients with hypercholesterolemia. Clinical Biochemistry 2009; 42, 2009 :666-671.
[5]. Immanuel S, Sanjaya AI . Albumin Cobalt Binding (ACB) Test: Its Role as a Novel Marker of Acute Coronary Syndrome. Acta Med Indones-Indones 2006; 38 :92-96.
[6]. Bar-Or D,Lau E, Winkler JV.A novel assay for cobalt albumin bindingand its potential as a marker for myocardial ischaemia-apreliminary report. J Emerg med2000,19;311-15.
[7]. Chawla R., Goyal N, Calton R and Goyal S. Ischemia Modified Albumin : A novel marker for acute coronary syndrome. Indian Journal of Clinical Biochemistry, 2006, 21 77-82.
[8]. Christenson RH, Duh SH, Sanhai WR, Wu AH, Holtman V, Painter P, Branham E, Apple FS, Murakami M, Morris DL.Characteristics of an albumin cobalt binding test for assessment of acute coronary syndrome patients: a multicenter study. Clin Chem.2001;47:464-470.

[9]. Bhagavan NV, Lai EM, Rios PA, Yang J, Ortega-Lopez AM, Shinoda H, Honda SA, Rios CN, Sugiyama CE, Ha CE. Evaluation of human serum albumin cobalt binding assay for the assessment of myocardial ischemia and myocardial infarction. Clin Chem. 2003;49:581-585.
[10]. Lee E, Eom JE, Jeon KH, Kim TH, Kim E, Jhon GJ, Kwon Y.Evaluation of albumin structural modifications through cobalt-albumin binding (CAB) assay. J Pharm Biomed Anal. 2014 ;91:17-23.

Most read articles by the same author(s)